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Background: Pseudomyxoma peritonei is a rare clinical 
condition characterized by mucin-secreting epithelial 
cells which lead to formation of jelly-like structures 
within the peritoneal cavity and the accumulation of 
mucinous ascites. Most commonly it arises from the intra-
abdominal spread of appendiceal mucinous tumors. 
Few therapeutic options exist, but a combination of 
cytoreductive surgery and hyperthermic intraperitoneal 
chemotherapy, as described by Sugarbaker, stands 
for the treatment of choice in many tertiary centers 
nowadays.
Case study: We present a 62-year-old female patient 
who was initially presented as acute appendicitis. 
Later pathohistological diagnosis of Pseudomyxoma 
peritonei just confirmed intraoperative suspicions. 
Definitive diagnosis was followed with a complete 
cytoreductive surgery and hyperthermic intraperitoneal 
chemotherapy. After a 10 year relapse-free follow 
up, she presented with colon adenocarcinoma and a 
recurrence of jelly-like incapsulated structures within 
the abdominal cavity.
Conclusion: In patients diagnosed with pseudomyxoma 
peritonei, according to current findings, best results are 
achieved using complete cytoreductive surgery and 
hyperthermic intraperitoneal chemotherapy. However, 
recurrences still do occur and there is no real consensus 
regarding their optimal treatment.
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Introduction
Pseudomyxoma peritonei is a rare clinical condition with 
unknown cause and estimated overall incidence of 1-2 
per million [1]. The primary tumor usually originates 
from the appendix, but can also appear in ovarium, 
urinary bladder or any other part of the gastrointestinal 
system [2]. Female patients are more likely affected. 
Synchronous tumors of appendix and ovaries were 
described, but recent immunohistochemical studies 
suggest that „synchronous“ ovarian tumor is actually a 
metastatic process of primary appendiceal tumor [3]. 
Pseudomyxoma peritonei begins as an appendiceal 
adenoma which starts to produce mucus intraluminally 
and consequently leads to obstruction and rupture 
of the appendix. Therefore, tumor cells are spread 
intraperitoneally, where they continue with their 
mucus production. Pseudomyxomal tumorous cells 
tend to characteristically accumulate around the liver, 
omentum and in the lower pelvic region, unlike some 
other gastrointestinal tumor metastases which usually 
incorporate close to their perforation site. As the tumor 
progresses, metastatic cells spread to entire abdomen, 
but there is always absence of tumor masses on the 
free portion of the small intestine, which is described 
as a pathognomonic sign [4, 5]. An intraabdominal 
accumulation of jelly-like masses causes unspecific 
symptoms like abdominal or pelvic pain, distension 
of abdomen, and infertility. After a long period of 
accumulation, eventually, mechanical obstruction of 
the gastrointestinal tract occurs. Because of that, early 
diagnosis is difficult to make and it is often misdiagnosed. 
Differential diagnosis in female patients is even harder 
as it includes ovarian tumors, which can also produce 
mucus and cause distension of the abdomen with 
similar symptoms. Therapy of pseudomyxoma peritonei 
depends on the tumor size and a stage of the disease. In 
the majority of patients, long term prognosis is poor and 
depends upon the histological type of tumor with 50% of 
5-year survival [6]. When possible, cytoreductive surgery 
combined with intraperitoneal chemotherapy shows 
best long-term results [7]. Other therapy options include 
„debulking“ surgery, classic intravenous chemotherapy 
or expectative follow-up. We report a case of a female 
patient diagnosed with pseudomyxoma peritonei 
who was treated by complete cytoreductive surgery 
and peritonectomy accompanied by hyperthermic 
intraperitoneal chemotherapy (HIPEC). The patient had 
uneventful recovery in a 10-year relapse-free follow up 
but then presented with colon adenocarcinoma and a 
recurrence of jelly-like incapsulated structures within 
the abdominal cavity.
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Case study
A 62-year old female patient presented to the emergency 
department with a seven-day history of constant 
periumbilical pain, localized to the right lower quadrant. 
8 months prior to arrival, she experienced the same 
symptoms which regressed spontaneously. Her medical 
history revealed hypertension and uterine myoma. 
By the time of examination, she did not feel nausea, 
anorexia, neither had diarrhea. Physical examination 
revealed an obese female patient with rebound 
tenderness over the right lower abdominal quadrant. 
Vital signs were within normal limits (RR 140/90mmHg, 
BPM 78/min). Laboratory findings showed an elevated 
white blood count (11,21x109/L) and CRP (80mg/L). 
The ultrasound study showed a collection of dense 
fluid at the ileocecal region, which was described as 
an abscess formation. The plain abdominal radiograph 
showed no signs of pneumoperitoneum. Pararectal 
laparotomy revealed the intraabdominal cavity fulfilled 
with gelatinous masses and numerous cystic lesions, 
which covered peritoneum and liver. Appendix was 
thickened >3 cm in the distal part but showed no signs of 
inflammation or rupture. Appendectomy was done with 
pathohistological diagnosis of carcinoid tumor of the 
appendix and peritoneal carcinomatosis. For the next 34 
months she was treated conservatively with an obvious 
deterioration of her clinical condition and progression of 
the radiological findings (Figure 1.). Her main complaint 
was distension of the abdomen accompanied with 
anorexia and constipation (Figure 2.). 
Laparotomy was done, intraabdominal jelly-like 
masses (Figure 3.) were evacuated and complete 
peritonectomy together with cytoreductive 
surgery followed by hyperthermic intraperitoneal 
chemotherapy (mitomycin/cisplatin) was undertaken. 
The pathohistological diagnosis was pseudomyxoma 
peritonei. 
Postoperative period passed uneventfully and the 
patient was in regular surgical and oncologic follow 
up for the next 10 years. During that period she 
was asymptomatic and felt occasional nausea and 
bloating. Because of sideropenic anemia, a diagnostic 
colonoscopy was undertaken, which revealed a stricture 
of the ileocolic anastomosis. Laparotomy showed 
infiltrating process at the location of the previously 
formed anastomosis. Tumorous process was resected 
and the new anastomosis was formed. During the 
procedure, a pseudocystic formation was noticed in 
the retrogastric area which was left untouched and the 
patient was radiologically reevaluated. CT of abdomen 
and pelvis revealed an unusual, well defined, lobulated 
cyst which was located in omental bursa and was in 
close contact with the pancreas (Figure 4.).
Additional PET/CT was done which showed a multicystic 
expansive formation under the left lobe of the liver 
which incorporates antral gastric region and shows 
no metabolic activity, probably due to the majority of 
jelly-like content. Relaparotomy was made and showed 
an egg-like white encapsulated process in the bursa 
omentalis which was in close connection with the 
surrounding structures, but does not infiltrate them 
(Figure 5. A). The tumor was easily removed and opened 
afterward. It was formed of mucinous and jelly-like 
content (Figure 5. B). The pathohistological diagnosis 
was mucin and lipoma.
Discussion
In the past, patients diagnosed with pseudomyxoma 
peritonei were treated by surgical reduction of the 
tumor and repeated drainages of mucinous ascites, with 
poor results and common relapses, which resulted in 
low quality of life. [8]. In 1980. Spratt et al. introduced 
hyperthermic intraperitoneal chemotherapy as a 
new therapy option [9]. A few years later, Sugarbaker 
proposed treatment of pseudomyxoma peritonei with 
the combined procedure, which included cytoreductive 
surgery accompanied by hyperthermic intraperitoneal 
chemotherapy [10]. Despite a lack of multicentric 
prospective randomized studies, literature published 
during the last two decades confirms the efficiency of 
the combined procedure, which became the treatment 
of choice in many tertiary centers worldwide nowadays 
[11-16]. It is usually used for appendiceal low-grade 
tumors with peritoneal dissemination [17], with overall 
10-year survival of 63% [18]. Miner et al. questioned the 
efficiency of complete cytoreductive surgery combined 
with HIPEC because of its radical approach and variety 
of perioperative complications. The study included a 
group of patients treated by series of less aggressive 
cytoreductions (average 2.2 surgeries per patient) and 
with selective usage of intraperitoneal chemotherapy 
with a median survival of 12.8 years for patients with 
low-grade tumor and only 4-year survival for patients 
with high-grade tumors. The overall 10-year survival was 
23% [8]. On the other hand, Sugarbaker et al. analyzed a 
similar group of patients, who were treated by primary 
aggressive cytoreduction (1.3 surgery per patient) 
followed by intraperitoneal chemotherapy and showed 
20-year survival of 70% [19]. The success of combined 
therapy lies in primary aggressive cytoreduction 
which tends to totally eradicate tumorous mass in just 
one radical surgical procedure which is followed by 
intraperitoneal chemotherapy directed towards the 
residual microscopic tumor. This kind of approach allows 
early and total removal of the tumor, which is not possible 
in a series of less aggressive palliative procedures, 
because of intraabdominal adhesions formation with 
every new laparotomy. Also, there is no evidence that 
perioperative morbidity and mortality are related to 
intraperitoneal chemotherapy. Possible complications 
are in fact related to duration and extensiveness of 
radical surgical procedure. Despite combined therapy, 
tumor relapses still occur and present a diagnostic and 
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therapeutic problem. Delhorme et al. analyzed a tumor 
recurrence in a group of patients treated by primary 
cytoreductive surgery and HIPEC. During an 85 months 
follow-up 26% of patients had a tumor relapse, with a 
median of 25 relapse free months. In the majority of cases 
(76%), primary relapse was localized intraperitoneally, 
as it is described in the reported case [20]. Even though 
the treatment of intraperitoneal recurrences is still 
debatable, redo surgery for isolated intraperitoneal 
recurrence is proposed by most of the authors [21-25]. 
There is an absence of consensus regarding redo HIPEC, 
considering its failure to prevent relapse of the disease. 
With no doubt, large randomized studies are necessary 
to define which groups of patients would have a benefit 
and should be treated by cytoreductive surgery and 
HIPEC. Described patient fits in a group of successfully 
treated patients with the combined method, despite 
intraabdominal status worsening and disease relapse 
after a 10-year follow-up.
Conclusion
There is a lack of evidence based guidelines which 
would define the best treatment options for patients 
diagnosed with pseudomyxoma peritonei. According 
to current findings, complete cytoreductive surgery 
and hyperthermic intraperitoneal chemotherapy 
is a treatment of choice nowadays. A fact that 
pseudomyxoma peritonei is a rare clinical condition 
shouldn’t lessen a need for further investigations which 
will lead to clear guidelines based on strong evidence. 
The authors declare that there is no conflict of interest.
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A) Preoperative MSCT of abdomen and pelvis showing diffuse collections of gelatinous material and mucus around liver, 
spleen, and intestines. B) Postoperative MCST of abdomen and pelvis after a complete cytoreductive surgery with HIPEC.
Figure 2.
  
On the left preoperative picture of the patient with massive distension of the abdomen. On the right postoperative 
picture of the patient with uneventful recovery.
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Figure 3.
       Intraoperative picture showing  
       evacuated gelatinous material  
       and mucus. 
Figure 4.
 
Abdominal CT scan of well defined, lobulated cyst in omental bursa which is in close contact with the pancreas.
Figure 5.
 
A) Intraoperative photo of the cyst located in retrogastric area protruding through the hepatic recess.  
B) Photo of the surgical specimen after extirpation and opening which revealed mucinous material.
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